Never miss a story

Get subscribed to our newsletter


×
Your work emails can affect your health, relationships Pixabay

US researchers have developed an experimental drug that potentially slows down the progression of Parkinson’s disease as well as its symptoms.

In experiments performed with cultures of human brain cells and live mouse models, researchers from the Johns Hopkins University in Maryland reported that the drug blocked the degradation of brain cells that is the hallmark of Parkinson’s disease.


“It is amazingly protective of target nerve cells,” said Ted Dawson, Professor at the University’s School of Medicine.

The drug, named NLY01, is similar to compounds used to treat diabetes and is expected to move to clinical trials this year.

If successful in humans, it could be one of the first treatments to directly target the progression of Parkinson’s, not just the muscle rigidity, spasmodic movements, fatigue, dizziness, dementia and other symptoms of the disorder, Dawson said in the paper published in the journal Nature Medicine.


Representational image. (IANS)

In a preliminary experiment in laboratory-grown human brain cells, Dawson’s team treated human microglia — a brain cell type that sends signals throughout the central nervous system in response to infection or injury — with NLY01 and found that they were able to turn the activating signals off.

Further, the researchers injected the mice with alpha-synuclein — the protein known to be the primary driver of Parkinson’s disease — and the mice treated with NLY01 maintained normal physical function and had no loss of dopamine neurons, indicating that the drug protected against the development of Parkinson’s disease.

Also Read: Fruit Bats Identified As Source Of Nipah Virus Outbreak in Kerala

In another experiment, the team used mice that were genetically engineered to naturally produce more human-type alpha-synuclein typically used to model human Parkinson’s disease that runs in families.

While under normal conditions, these so-called transgenic mice will succumb to the disease in 387 days, those treated with NLY01 extended the lives by over 120 days.

However, the experimental drug must still be tested for safety as well as effectiveness in people, Dawson cautioned. (IANS)


Popular

Pixabay

Samsung Electronics, the world's number two foundry firm behind Taiwan's TSMC, announced in May that it will build a $17 billion fab in the US.

Samsung Electronics will quickly decide on a foundry investment in the US, a senior executive said Tuesday, as the South Korean tech giant seeks to become the world's number one player in the logic chip and foundry sectors. Samsung Electronics, the world's number two foundry firm behind Taiwan's TSMC, announced in May that it will build a $17 billion fab in the US.

Samsung's de facto leader Lee Jae-yong is widely speculated to visit the US, possibly next month, to finalise the site, with the city of Taylor, Texas, emerging as the strongest candidate. Other candidates include Arizona, New York, and Austin, Texas. Kim Ki-nam, Vice Chairman and CEO of Samsung's device solutions division, said it takes time for the company to review all the factors such as "infrastructure, site, personnel and state incentives," and make a final decision.

"We are trying to make a decision as soon as possible," Kim told reporters on the sidelines of the Korea Electronics Show 2021, which is under way at an exhibition center in southern Seoul. He made the comments when asked whether Samsung will make an investment within this year. He did not elaborate, reports Yonhap news agency.

Separately, Kim said the company has been "calmly" preparing answers to a recent request by the US Department of Commerce about its semiconductor business. The US has asked global chipmakers, including Samsung, to share information on inventories and demanded other details by November 8 to "help improve trust and transparency within the supply chain." The request spawned concerns about the leak of chipmakers' major trade secrets. (IANS/ MBI)


Keep Reading Show less
Wikimedia Commons

'Vikram Vedha' is a Hindi remake of the runaway Tamil hit of the same name which was released in 2017.

It's been over two years since Hrithik Roshan appeared on celluloid. Fans have been waiting to witness his next performance on the silver screen and it seems like their wishes will be soon granted. Earlier, Hrithik had made an announcement about getting back to shooting schedule for the upcoming film 'Vikram Vedha'. And now, it's learnt that the actor has recently wrapped the first ever action sequence from the film.

The news came out when a few stuntmen from the film's set shared pictures of the sequence wrap. The stunt sequences seem to be quite crazy as suggested by the stuntmen. Talking about the same, a stuntman posted on his instagram as he wrote, "Wrapped up the first action sequence of Vikram Vedha. A big 'Thank you' to @parvez.shaikhh sir for this opportunity. Wouldn't have been possible without you ?? @hrithikroshan."

Another stuntman posted, "First craziest action sequence have done (sic).!! Cheer's To @hrithikroshan @parvez.shaikhh @stuntindia1 and all the stunt boys.!!"

'Vikram Vedha' is a Hindi remake of the runaway Tamil hit of the same name which was released in 2017. While the original action thriller starred R. Madhavan and Vijay Sethupathi, the Hindi version will see Hrithik Roshan squaring off against Saif Ali Khan. (IANS/ MBI)


Keep Reading Show less
VOA

Japan's former Princess Mako, the elder daughter of Crown Prince Akishino and Crown Princess Kiko, and her husband Kei Komuro, look at each other during a press conference to announce their marriage at a hotel in Tokyo, Japan, Oct. 26, 2021

The niece of Japanese Emperor Naruhito, Princess Mako, married a commoner Tuesday, relinquishing her royal status following a heavily scrutinized, controversial four-year engagement.

The Japanese Imperial Household Agency issued a statement announcing the marriage of Mako to Kei Komuro, both 30 years old.

Keep reading... Show less